The role of Beta-1 receptor gene polymorphism in Beta-Blocker therapy for vasovagal syncope
BACKGROUND: Vasovagal syncope (VVS) is a common clinical condition involving genetic background. The role of beta-blockers in the treatment is controversial.
OBJECTIVE: The aim of this study was to investigate the effect of beta-1 gene polymorphism on beta-blocker therapy in patients with VVS.
METHODS: We included 123 patients who were diagnosed with VVS after the tilttable test. We searched for the polymorphism Arg389Gly (rs1801253) in the beta-1 adrenoceptor gene.
RESULTS: Overall, 64 patients (52%) had Arg389Arg with Arg389Arg genotype were more frequent compared with patients having Arg389Gly genotype (total syncopal episodes [TSE], 7.9 ± 3.7 vs. 6.4 ± 3.0; p = 0.012). TSE in patients with Arg389Arg genotype decreased significantly after 18 months of beta-blocker treatment (7.9 ± 3.7 vs. 3.0 ± 1.4, p < 0.001). After 18 months of beta-blocker treatment, patients with Arg389Arg genotype had significantly fewer syncopal episodes than patients with Arg389Gly genotype (3.0 ± 1.4 vs. 6.8 ± 3.2, p < 0.001).
CONCLUSIONS: Results of beta-blocker therapy in patients with Arg389Arg genotype suggest that VVS pathophysiology is a multifactorial condition, with genetic, psychological, and environmental components, and therefore, treatment selection can be based on gene polymorphism.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:72 |
---|---|
Enthalten in: |
Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion - 72(2020), 5 vom: 07. Mai |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Atici, Adem [VerfasserIn] |
---|
Links: |
---|
Themen: |
---|
Anmerkungen: |
Date Revised 22.02.2024 published: Print-Electronic Citation Status Publisher |
---|
doi: |
10.24875/RIC.20003319 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM316232122 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM316232122 | ||
003 | DE-627 | ||
005 | 20240229142916.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.24875/RIC.20003319 |2 doi | |
028 | 5 | 2 | |a pubmed24n1303.xml |
035 | |a (DE-627)NLM316232122 | ||
035 | |a (NLM)33053571 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Atici, Adem |e verfasserin |4 aut | |
245 | 1 | 4 | |a The role of Beta-1 receptor gene polymorphism in Beta-Blocker therapy for vasovagal syncope |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 22.02.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status Publisher | ||
520 | |a BACKGROUND: Vasovagal syncope (VVS) is a common clinical condition involving genetic background. The role of beta-blockers in the treatment is controversial | ||
520 | |a OBJECTIVE: The aim of this study was to investigate the effect of beta-1 gene polymorphism on beta-blocker therapy in patients with VVS | ||
520 | |a METHODS: We included 123 patients who were diagnosed with VVS after the tilttable test. We searched for the polymorphism Arg389Gly (rs1801253) in the beta-1 adrenoceptor gene | ||
520 | |a RESULTS: Overall, 64 patients (52%) had Arg389Arg with Arg389Arg genotype were more frequent compared with patients having Arg389Gly genotype (total syncopal episodes [TSE], 7.9 ± 3.7 vs. 6.4 ± 3.0; p = 0.012). TSE in patients with Arg389Arg genotype decreased significantly after 18 months of beta-blocker treatment (7.9 ± 3.7 vs. 3.0 ± 1.4, p < 0.001). After 18 months of beta-blocker treatment, patients with Arg389Arg genotype had significantly fewer syncopal episodes than patients with Arg389Gly genotype (3.0 ± 1.4 vs. 6.8 ± 3.2, p < 0.001) | ||
520 | |a CONCLUSIONS: Results of beta-blocker therapy in patients with Arg389Arg genotype suggest that VVS pathophysiology is a multifactorial condition, with genetic, psychological, and environmental components, and therefore, treatment selection can be based on gene polymorphism | ||
650 | 4 | |a Journal Article | |
700 | 1 | |a Rasih-Sonsoz, Mehmet |e verfasserin |4 aut | |
700 | 1 | |a Ali-Barman, Hasan |e verfasserin |4 aut | |
700 | 1 | |a Durmaz, Eser |e verfasserin |4 aut | |
700 | 1 | |a Demirkiran, Ahmet |e verfasserin |4 aut | |
700 | 1 | |a Gulsen, Kamil |e verfasserin |4 aut | |
700 | 1 | |a Elitok, Ali |e verfasserin |4 aut | |
700 | 1 | |a Onur, Imran |e verfasserin |4 aut | |
700 | 1 | |a Sahin, Irfan |e verfasserin |4 aut | |
700 | 1 | |a Kaya Bilge, Ahmet |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion |d 1949 |g 72(2020), 5 vom: 07. Mai |w (DE-627)NLM00017985X |x 0034-8376 |7 nnns |
773 | 1 | 8 | |g volume:72 |g year:2020 |g number:5 |g day:07 |g month:05 |
856 | 4 | 0 | |u http://dx.doi.org/10.24875/RIC.20003319 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 72 |j 2020 |e 5 |b 07 |c 05 |